TY - JOUR
T1 - Oncologic Outcomes of Partial Nephrectomy for Stage T3a Renal Cell Cancer
AU - Shvero, Asaf
AU - Nativ, Ofer
AU - Abu-Ghanem, Yasmin
AU - Zilberman, Dorit
AU - Zaher, Bahouth
AU - Levitt, Max
AU - Fridman, Eddie
AU - Portnoy, Orith
AU - Ramon, Jacob
AU - Dotan, Zohar A.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/6
Y1 - 2018/6
N2 - We present our long-term multicenter experience with partial nephrectomy for locally advanced tumors (stage pT3a) and compare the oncologic outcomes with those of similar patients treated with radical nephrectomy. The cohort size was 134 patients. Surgery type was not a predictor of the oncologic outcomes at the 5-year follow-up point. Our findings suggest that partial nephrectomy can be considered for T3a tumors and, thus, avoid the long-term complications of radical nephrectomy. Future studies are needed for validation. Background: Partial nephrectomy (PN) for clinical stage T3 tumors is controversial. Radical nephrectomy (RN) has been associated with a greater rate of chronic kidney disease, an increased risk of cardiovascular disease, and increased mortality compared with PN. We present our long-term 2-center experience with PN for stage pT3a tumors and compare the oncologic outcomes with those of similar patients treated with RN. Materials and Methods: We reviewed the data from all patients who had undergone nephrectomy for renal cell carcinoma from 1987 to 2015 in 2 medical centers. The study included 134 patients with pathologic stage T3a tumors, of whom 48 and 86 underwent PN and RN, respectively. We compared the 2 groups (PN and RN) using univariate and multivariate analyses. Results: The tumors of all patients with pathologic stage T3a who had undergone PN had been pathologically upstaged from clinical stage T1 or T2. Univariate and multivariate analyses revealed tumor size was significantly different statistically between the study groups (median, 7.0 cm in RN group vs. 4.0 cm in PN group; P <.001). Surgery type was not a predictor of local recurrence (P =.978), metastatic progression (P =.972), death from renal cancer (P =.626), or death from all causes (P =.974) at the 5-year follow-up point. Conclusion: The results of the present study have shown similar oncologic outcomes between 48 patients with stage pT3a renal cancer who underwent PN and 86 patients who underwent RN. Although PN was not performed on clinical T3a tumors, our findings suggest that PN can also be considered for these tumors and, thus, avoid the long-term complications of RN. However, strict follow-up protocols are mandatory.
AB - We present our long-term multicenter experience with partial nephrectomy for locally advanced tumors (stage pT3a) and compare the oncologic outcomes with those of similar patients treated with radical nephrectomy. The cohort size was 134 patients. Surgery type was not a predictor of the oncologic outcomes at the 5-year follow-up point. Our findings suggest that partial nephrectomy can be considered for T3a tumors and, thus, avoid the long-term complications of radical nephrectomy. Future studies are needed for validation. Background: Partial nephrectomy (PN) for clinical stage T3 tumors is controversial. Radical nephrectomy (RN) has been associated with a greater rate of chronic kidney disease, an increased risk of cardiovascular disease, and increased mortality compared with PN. We present our long-term 2-center experience with PN for stage pT3a tumors and compare the oncologic outcomes with those of similar patients treated with RN. Materials and Methods: We reviewed the data from all patients who had undergone nephrectomy for renal cell carcinoma from 1987 to 2015 in 2 medical centers. The study included 134 patients with pathologic stage T3a tumors, of whom 48 and 86 underwent PN and RN, respectively. We compared the 2 groups (PN and RN) using univariate and multivariate analyses. Results: The tumors of all patients with pathologic stage T3a who had undergone PN had been pathologically upstaged from clinical stage T1 or T2. Univariate and multivariate analyses revealed tumor size was significantly different statistically between the study groups (median, 7.0 cm in RN group vs. 4.0 cm in PN group; P <.001). Surgery type was not a predictor of local recurrence (P =.978), metastatic progression (P =.972), death from renal cancer (P =.626), or death from all causes (P =.974) at the 5-year follow-up point. Conclusion: The results of the present study have shown similar oncologic outcomes between 48 patients with stage pT3a renal cancer who underwent PN and 86 patients who underwent RN. Although PN was not performed on clinical T3a tumors, our findings suggest that PN can also be considered for these tumors and, thus, avoid the long-term complications of RN. However, strict follow-up protocols are mandatory.
KW - Carcinoma
KW - Kidney
KW - Nephron-sparing surgery
KW - Surgical oncology
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85034789443&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2017.10.016
DO - 10.1016/j.clgc.2017.10.016
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 29174471
AN - SCOPUS:85034789443
SN - 1558-7673
VL - 16
SP - e613-e617
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
ER -